Antiplatelet therapy: present status and future prospects

Justin R Hamilton1, Zane Kaplan, Shaun P Jackson

  • 1Australian Centre for Blood Diseases, Monash University, 6th Level, Burnet Building, AMREP Campus, 89 Commercial Road, Melbourne, Victoria 3004, Australia +61 3 9903 0122 ; +61 3 9903 0228 ; Justin.Hamilton@med.monash.edu.au.

Insights

Platelet accumulation causes arterial thrombosis, leading to heart attacks and strokes. Current antiplatelet therapies aim to improve treatment safety and effectiveness for cardiovascular disease management.

Area of Science:

  • Cardiovascular Science
  • Hematology
  • Pharmacology

Background:

  • Platelet accumulation at vascular injury sites drives arterial thrombosis.
  • Arterial thrombosis underlies acute coronary syndromes and ischemic stroke, major causes of death.
  • Platelets are a primary therapeutic target in cardiovascular disease management.

Purpose of the Study:

  • To review the current landscape of antiplatelet therapy.
  • To explore future strategies for enhancing antiplatelet agent safety and efficacy.

Main Methods:

  • Literature review and perspective synthesis.
  • Analysis of current antiplatelet drug classes.
  • Discussion of emerging therapeutic approaches.

Main Results:

  • Antiplatelet therapy is crucial but faces challenges in balancing efficacy and bleeding risk.
  • Existing agents target various platelet activation pathways.
  • Novel strategies are being developed to optimize therapeutic outcomes.

Conclusions:

  • Antiplatelet therapy remains a cornerstone in managing thrombotic cardiovascular diseases.
  • Future directions focus on personalized medicine and improved safety profiles.
  • Optimizing antiplatelet strategies is essential for reducing morbidity and mortality.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...